Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix).
about
The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.Delaying the oocyte maturation trigger by one day leads to a higher metaphase II oocyte yield in IVF/ICSI: a randomised controlled trialSerum Oestradiol Pattern during Coasting is Different in Antagonist Cycles Compared with Long Agonist Cycles in In Vitro FertilisationAssociation between the proportion of dominant follicles and oocyte developmental competenceOptimized hormonal stimulation is critical for production of viable embryos and establishment of subsequent implantation.Effect of in vivo GnRH agonist and GnRH antagonist on hCG and insulin-stimulated progesterone production by human granulosa-lutein cells in vitro.GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI-ET with a GnRH agonist protocol.The extrapituitary effects of GnRH antagonists and their potential clinical implications: a narrated review.The value of delaying hCG administration to enable maturation of medium-sized follicles in patients undergoing superovulation for IVF/ICSI.The follicular hormonal profile in low-responder patients undergoing unstimulated cycles: Is it hypoandrogenic?Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer.Association of follicular fluid volume with membrane stretchability of human metaphase II oocytes following the gonadotropin-releasing hormone agonist protocol during intracytoplasmic sperm injectionEffect of gonadotropin-releasing hormone agonist and antagonist on steroidogenesis of low responders undergoingin vitrofertilization
P2860
Q24816913-95E8F3D9-B351-4360-ADE0-CA4A26F62910Q33559874-C692F500-32EF-4AE1-983E-56B3C991FF35Q33974030-AFFDB94D-474C-4000-8F2E-C7329088BCBEQ34603830-BB7EDC24-440F-41BC-AEA4-282768FF4447Q36270384-0F296F2B-C236-4625-B56F-DCAB828CC2ACQ36271008-FAE3CDBF-2B83-475B-92D0-E89FE76C0083Q36308688-73DFF742-0529-4CC5-AE78-10A2BB6B5B8FQ38046587-A5B77728-1AFB-41F9-AC5D-8BA0D24EF74AQ47891338-4DB9355B-747D-499B-B8F6-27F4F13589B1Q48639009-FA07EEBE-97B9-4BC9-983F-284E2C52625EQ48723145-BFF80677-6691-4E76-8579-D5214889B436Q56550339-201C2558-77B1-404D-9872-5F780939384FQ58323742-F21084EF-A124-4096-9CE3-1456D92ED602
P2860
Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix).
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Human ovarian steroid secretio ...... ersus antagonist (cetrorelix).
@en
Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist
@nl
type
label
Human ovarian steroid secretio ...... ersus antagonist (cetrorelix).
@en
Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist
@nl
prefLabel
Human ovarian steroid secretio ...... ersus antagonist (cetrorelix).
@en
Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist
@nl
P2093
P2860
P356
P1433
P1476
Human ovarian steroid secretio ...... ersus antagonist (cetrorelix).
@en
P2093
A Landazábal
A Pellicer
J A Garcia-Velasco
P2860
P304
P356
10.1093/HUMREP/16.12.2533
P407
P577
2001-12-01T00:00:00Z